D
Daniel M. Sullivan
Researcher at University of South Florida
Publications - 147
Citations - 8411
Daniel M. Sullivan is an academic researcher from University of South Florida. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 47, co-authored 147 publications receiving 7773 citations. Previous affiliations of Daniel M. Sullivan include University of Wisconsin–Milwaukee.
Papers
More filters
Journal ArticleDOI
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.
Adil Daud,Ronald C. DeConti,S. Andrews,P. Urbas,Adam I. Riker,Vernon K. Sondak,Pamela N. Munster,Daniel M. Sullivan,Kenneth E. Ugen,Jane L. Messina,Richard Heller +10 more
TL;DR: This report describes the first human trial, to the authors' knowledge, of gene transfer utilizing in vivo DNA electroporation and indicated this modality to be safe, effective, reproducible, and titratable.
Journal ArticleDOI
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Timothy A. Yap,Li Yan,Amita Patnaik,Ivy Fearen,David Olmos,Kyriakos P. Papadopoulos,Richard D. Baird,Liliana Delgado,Adekemi Taylor,Lisa Lupinacci,Ruth Riisnaes,Lorna Pope,Simon P. Heaton,George Thomas,Michelle D. Garrett,Daniel M. Sullivan,Johann S. de Bono,Anthony W. Tolcher +17 more
TL;DR: MK-2206 was well tolerated, with evidence of AKT signaling blockade, and Rational combination trials are ongoing to maximize clinical benefit with this therapeutic strategy.
Journal ArticleDOI
Persistent Activation of Stat3 Signaling Induces Survivin Gene Expression and Confers Resistance to Apoptosis in Human Breast Cancer Cells
Tanya Gritsko,Ann C. Williams,James Turkson,Satoshi Kaneko,Tammy Bowman,Mei Huang,Sangkil Nam,Ibrahim Eweis,Nils M. Diaz,Daniel M. Sullivan,Sean J. Yoder,Steve Enkemann,Steven A. Eschrich,Ji-Hyun Lee,Craig A. Beam,Jin Cheng,Susan Minton,Carlos A. Muro-Cacho,Richard Jove +18 more
TL;DR: The findings suggest that activated Stat3 signaling contributes to breast cancer progression and resistance to chemotherapy by, at least in part, inducing expression of the antiapoptotic protein, Survivin.
Journal ArticleDOI
Nuclear export of proteins and drug resistance in cancer
TL;DR: It is believed that the future development of low-toxicity, small-molecule CRM1 inhibitors may provide a new approach to treating cancer.
Journal ArticleDOI
Activation of Stat3 in Primary Tumors from High-Risk Breast Cancer Patients Is Associated with Elevated Levels of Activated Src and Survivin Expression
Nills Diaz,Susan Minton,Charles E. Cox,Tammy Bowman,Tanya Gritsko,Roy Garcia,Ibrahim Eweis,Marek Wloch,Sandy Livingston,Ed Seijo,Alan B. Cantor,Ji-Hyun Lee,Craig A. Beam,Daniel M. Sullivan,Richard Jove,Carlos A. Muro-Cacho +15 more
TL;DR: These findings suggest that specific Stat3 or Src inhibitors could offer clinical benefits to patients with breast cancer and suggest important roles for elevated activities of Stat3 and Src, as well as Survivin expression, in malignant progression of breast cancer.